SCOPE CLI (Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia) - Pilot Phase 1
Diseases of the Cardiovascular System
What is the purpose of this trial?
An estimated 8 million individuals in America are affected by peripheral arterial disease (PAD). One of its extreme expression is Critical Limb Ischemia (CLI). It is one of the most severe vascular conditions associated with devastating outcomes, including poorly healing wounds, extreme pain, and a high amputation risk. It is also one of the deadliest conditions, with 6-month and 5-year mortality rates estimated to be 20 and above 50% respectively.
The SCOPE-CLI (Pilot Study) is made up of three centers including Yale New Haven Hospital. During their regular visits to their doctors, study staff will collect information about the symptoms and treatments of patients who have severely clogged arteries to learn about their outcomes after one year.
The overall goal of the SCOPE-CLI study is to document the difference in treatment approaches and examine the associations of patient and treatment characteristics with outcomes. The researchers hope to determine whether improved quality of care can be traced to improved health status, fewer amputations, and other adverse limb events.
- Ages18 years and older
- Trial withSaint Luke's Hospital
- Start Date12/21/2020
- End Date12/30/2021
- Last Updated01/11/2021
- Study HIC#2000028818